NeuroMetrix Inc. of Waltham said Tuesday that it has signed a distribution agreement that will pave the way for a diabetes diagnostic device to become available in China, a country where diabetes is prevalent.
The NeuroMetrix device in question is called the NC-stat DPNCheck, a rapid point-of-care test for early detection of diabetic peripheral neuropathy, or DPN. DPN affects more than half of people with diabetes. DPN is the primary trigger for diabetic foot ulcers which may require lower extremity amputations, the company said in a press release.
NeuroMetrix signed its distribution agreement with Omron Medical Devices. That firm is a subsidiary of Omron Healthcare China, a manufacturer and distributor of medical screening and wellness products. Earlier this year, NeuroMetrix and Omron Healthcare Co. Ltd. announced a partnership for the exclusive distribution of NC-stat DPNCheck in Japan.
According to the International Diabetes Federation, the estimated worldwide population of people with diabetes is 371 million, and early a quarter of that total is in China.
“Omron has a strong and growing presence in China to compliment its global reach,” Shai N. Gozani M.D., president and chief executive of NeuroMetrix, said in a statement. “We are building an effective working relationship with Omron as we navigate the Japan regulatory process and prepare for commercial launch. We are pleased to join with Omron in bringing NC-stat DPNCheck to the large Chinese diabetes market.”